NCT06966388

Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

Pilot Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Virginia Commonwealth University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.

Detailed description

Patients will use azelaic acid twice daily (morning and evening) beginning 1 week before radiation treatment, and will continue use until 3 weeks after completion of radiation treatment

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Azelaic Acid	A thin layer of Azelaic acid should be applied to the entire area of radiation treatment twice daily, each day of the week (including weekends) starting one week prior to the start of radiation, then during the entire course of radiation treatment (usually 3-5 weeks), and for 3 weeks following the completion of radiation treatment.

Timeline

• Start date: 2025-08-13
• Primary completion: 2026-11-30
• Completion: 2026-11-30
• First posted: 2025-05-11
• Last updated: 2026-01-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study